About GCCL

With an exclusive lab service available for clinical trials and a logistics system that meets global quality standards,
GCCL is building trust with over 200 partners in Asia by providing a sample analysis service spanning
the entire cycle of clinical trials to meet customer demands.

Company News

홈   >   About GCCL   >   Newsroom   >   Company News

Meet us at Bio Asia-Taiwan 2025

2025. 06. 27

Meet us at Bio Asia-Taiwan 2025

Hello from GCCL.GCCL, a leading central lab based in APAC, is exhibiting at BIO Asia-Taiwan 2025 from July 24–28 in Taipei!Bio Asia–Taiwan is the largest biotech event in Asia, attracting over 130,000 participants and more than 900 global companies each year.At this year’s event, GCCL will showcase its customized analytical services and capabilities as a leading APAC central lab.📍 BIO Asia-Taiwan 2025 🗓️ July 24 (Thu) – July 27 (Sun), 2025 🔗 https://expo.bioasiataiwan.com/en/📌 Taipei, TaiwanMeet our Team at Bio Asia-Taiwan 2025💊 KwanGoo Cho, CEO📣 Dr.JaeWook Hyeon, Team Leader of R&D Unit👩‍💼 Harry Hong,  Global Business Development Manager🙋‍♀️ Eunkyu Jin, Global Business Development🌏 Why GCCL? In today’s drug development landscape, speed and data reliability are more critical than ever.At GCCL, we’re not just a lab that performs clinical trial analysis.We’re a strategic partner that understands project flow and aligns with your clinical development plan.💡 More than just analysis—your central lab from day one From Central Lab and Bioanalytical Lab to our dedicated R&D Lab, we provide comprehensive support - Sample management, Project management, Bio-logistics - across every stage of clinical development.🔬 Expertise across indications and modalities—from oncology to cell & geneWe deliver tailored analytical capabilities to meet your program’s specific indication and modality,supporting everything from biosimilars to first-in-class therapies with a wide range of validated platforms. 📊 Turning data into trust—with G-HUB & LIMS-based real-time managementOur proprietary portal, G-HUB, offers full transparency and real-time tracking of sample flow, logistics, and test results—seamlessly integrated with our LIMS. 🌐 A global network built on 1,300+ projects—from Asia to the worldHeadquartered in Korea, GCCL brings deep experience from global collaborationswith pharmaceutical companies and CROs across APAC and beyond. Please request a 1:1 partnering meeting via the BIO system or feel free to contact us!📩 Email: GCCL@gccorp.comWe look forward to meeting you at BIO Asia-Taiwan 2025 as your trusted global partner for end-to-end clinical trial sample analysis.GCCL is committed to being your most reliable clinical trial partner, delivering value and trust across every project.Click the banner below to learn more about us!

Read more
Introduce GCCL's All-in-One Lab Service for Clinical Sample Analysis

2025. 06. 23

Introduce GCCL's All-in-One Lab Service for Clinical Sample Analysis

GCCL, Your All-in-One Lab for Clinical Sample AnalysisAs the complexity and scale of clinical trials continue to grow, the need for a trusted partner to deliver accurate, timely, and compliant sample analysis has never been greater.GCCL, a GCLP-certified organization based in Korea, offers a full spectrum of clinical sample analysis services to support global trials—centrally coordinated across our Central Lab, Bioanalytical Lab, R&D Lab, and Logistics Operations.Our newly released brochure introduces how GCCL brings integrated solutions to the clinical research landscape.Proven Experience, Trusted by Global SponsorsSince 2019, GCCL has supported over 1,200 clinical projects ranging from early-phase studies to large-scale Phase III trials. We analyze more than 34,000 vials every month, and have successfully conducted 200+ method validations in compliance with FDA, EMA, and ICH M10 guidelines.We offer indication-specific analysis across oncology, CNS, infectious disease, cell & gene therapy, and more—tailoring every assay to meet the scientific and regulatory demands of each trial.Comprehensive Services Across the Clinical Sample LifecycleFrom the moment a sample leaves the clinical site, GCCL ensures complete control and traceability. Our dedicated cold-chain logistics network, backed by real-time monitoring and qualified global vendors, guarantees sample integrity throughout the journey.Once received, samples are processed and managed through our barcode-based tracking system and multi-temperature storage infrastructure, ensuring accuracy and compliance with regulatory standards. What distinguishes GCCL is the seamless integration across our specialized laboratory units:Our Central Lab supports all clinical phases with over 5,000 validated test items, covering a full range of safety and efficacy parameters essential for global trials.The Bioanalytical Lab provides advanced analysis of PK/PD, ADA, NAb, and biomarkers, utilizing cutting-edge platforms including LC-MS/MS, LBA, and ddPCR to ensure analytical precision.For studies requiring customized approaches, our R&D Lab offers method development and validation, applying advanced technologies to support diverse indications and evolving protocols.These operations are unified through our G-HUB platform, which gives sponsors real-time access to study setup, kit tracking, sample status, and data review—enhancing visibility, efficiency, and compliance.You can find out more about our All-in-One Lab in the leaflet below :-)  We will always continue to be the best clinical trial partner for our customers.Click the banner below to learn more about GCCL!

Read more
Partnering at INTERBIZ KOREA

2025. 06. 20

Partnering at INTERBIZ KOREA

Hello. This is GCCL, your trusted clinical sample analysis partner.We’re excited to announce our participation in the upcoming INTERBIZ Bio Partnering & Investment Forum 2025, held from July 2 to July 4 at Phoenix Island, Jeju.As a partnering company, GCCL will be joining networking sessions with leading Korean biopharma companies and CROs, exploring opportunities for collaboration in clinical development.📍 INTERBIZ Bio Partnering & Investment Forum 2025 🗓️ July 2 (Wed) – July 4 (Fri), 2025 📌 Phoenix Island, Jeju, Korea – Participating in business partnering sessions 🔗 https://www.interbiz.or.kr/interbiz/index.php✉️ Partnering inquiries: : GCCL@gccorp.comSince 2002, INTERBIZ has grown into Korea’s largest open innovation platform in the bio-health sector. It brings together stakeholders across industry, academia, research institutes, startups, and venture companies to explore collaboration in drug development, technology transfer, R&D partnerships, and investment.Now in its 23rd year, the forum continues to serve as a key venue for building partnerships and creating synergy across the life science ecosystem.GCCL is a GCLP-certified central lab and clinical sample analysis CRO that supports the full drug development lifecycle.With our integrated Bioanalytical Lab, Central Lab, and R&D Lab platforms, we’ve been a reliable partner to domestic and global pharmaceutical companies and CROs. At INTERBIZ 2025, we look forward to connecting with:✔ Korean drug developers✔ Clinical CRO professionalsWe welcome the opportunity to share insights on sample analysis-based collaboration models and analytical strategies tailored to each R&D phase. As your end-to-end analytical partner in clinical development, GCCL is committed to delivering value, trust, and scientific excellence.Click the banner below to learn more about us! 

Read more
GCCL Executive Director Yuhwa Choi Appointed as a Member of the Safety Evaluation Subcommittee

2025. 06. 17

GCCL Executive Director Yuhwa Choi Appointed as a Member of the Safety Evaluation Subcommittee

Hello, this is GCCL!Ms. Yuhwa Choi, COO of GCCL, has been appointed as a member of the“Safety Evaluation Subcommittee” of the R&D Expert Committee of the Food and Drug Regulatory Science Innovation Council, organized by the National Institute of Food and Drug Safety Evaluation under the Ministry of Food and Drug Safety.The R&D Expert Committee of the Regulatory Science Innovation Councilis an official advisory body that establishes policies and execution frameworks to ensure the safety and foster innovation in the food and pharmaceutical sectors.💊 Establishing the basic and implementation plans for regulatory science R&D 📜 Setting policy and budget directions 🥼 Supporting product development and cultivating expertsThis official advisory committee is composed of experts from industry, academia, research, and government, ensuring both professionalism and fairness.Under the committee, there are three subcommittees: Planning & R&D, Product Support, and Human Resource Development.In addition, specialized committees are formed for detailed policy execution, and Ms. Choi serves on the ‘Safety Evaluation’ committee.GCCL provides comprehensive sample analysis services throughout the entire new drug development cycle,operating Central Lab, Bioanalytical Lab, and R&D Lab.We are honored and proud that GCCL’s expertise has been nationally recognized through this appointment.Beyond being just an analysis service provider,GCCL serves as a trusted partner in regulatory policy development and industry-policy integration,growing together with domestic and global pharmaceutical companies.We will continue to contribute to Korea's regulatory science development and strengthen the drug development ecosystem,and strive to become a global-standard partner combining both expertise and public responsibility.We will always strive to be your most trusted partner in clinical trials. Want to learn more about GCCL? Click the banners below!

Read more
Partnering at Bio International 2025

2025. 05. 21

Partnering at Bio International 2025

Hello from GCCL (Global Clinical Central Lab)!We are excited to announce that GCCL will be participating in the BIO International Convention 2025,the world’s largest biotechnology event, held from June 16 to 19, 2025 at the Boston Convention & Exhibition Center.Meet the GCCL Partnering Team at BIO USA 2025💊 KwanGoo Cho, CEO📣 Yuwha Choi, COO👩‍💼 Sandra Woo, Team Leader, Global Business DevelopmentWith participation from over 1,000 biotech companies and organizations from more than 60 countries,the BIO USA is a premier global partnering event. GCCL will leverage this opportunity to highlight our position as the largest Central Lab in Asia and enhance our global visibility.We aim to connect with global pharmaceutical companies, biotechs, and CROs to explore opportunities for collaboration as a trusted bioanalytical partner throughout the drug development journey.Our key strengths include:✅ Quality assurance system based on GCLP, CAP, and ISO15189 certifications✅ Specialized platforms for Oncology, Infectious Diseases, and Cell & Gene Therapy (CGT)✅ Advanced infrastructure including LIMS and ddPCR systems✅ Analytical capabilities as an APAC Central Lab with a strong global networkFor partnering or collaboration inquiries, feel free to contact us at:✉️ GCCL@gccorp.comWe look forward to meeting you at BIO USA 2025 as your trusted global partner for end-to-end clinical trial sample analysis.GCCL is committed to being your most reliable clinical trial partner, delivering value and trust across every project.Click the banners below to learn more about GCCL.

Read more
Meet us at ASCO 2025

2025. 05. 16

Meet us at ASCO 2025

Hello, we are GCCL (Global Clinical Central Lab), a specialized clinical trial sample analysis organization.From May 31 to June 2, 2025, we will participate in the world's largest oncology conference,ASCO 2025 (American Society of Clinical Oncology), at the KoNECT Korea Pavilion (Booth #33143)held at McCormick Place in Chicago, USA, to build networks with global sponsors and CROs. Visit GCCL at ASCO 2025 📍 Booth #33143 (KoNECT Pavilion)📅 Exhibition Dates: May 31 (Sat) – June 2 (Mon)✉️ Meeting Inquiries: GCCL@gccorp.comASCO brings together over 40,000 oncology professionals from around the worldincluding global pharmaceutical companies, biotechs, CROs, research institutions, and government agenciesto share the latest strategies and clinical data and explore new collaboration opportunities. Through this participation, GCCL aims to expand its global client outreachand solidify its position as the leading central lab in the Asia-Pacific region.GCCL CEO, KwanGoo Cho, and Global Manager, Harry Hong, will attend the event in person,engaging in networking and partnering meetings with global stakeholders,while gaining insights into the latest industry trends and opportunities.🌐 Why Visit GCCL at ASCO?✅ CAP accreditation and GCLP-compliant global quality system✅ State-of-the-art labs equipped with ddPCR, LIMS, and more✅ Extensive experience in oncology-focused analysis and global clinical trial projectsWe hope ASCO 2025 will offer you a glimpse into the future of oncology innovations and global collaboration.GCCL looks forward to meeting you at ASCO 2025 as your trusted global partner in end-to-end bioanalytical services for drug development.We are committed to continuing as your trusted partner in clinical research. Click the banner below to learn more about GCCL!

Read more
GCCL will join the Partnering Meetings at BIO KOREA International Convention

2025. 04. 23

GCCL will join the Partnering Meetings at BIO KOREA International Convention

Hello, we are GCCL (Global Clinical Central Lab), a clinical trial bioanalytical service provider.From May 7 (Wed) to May 9 (Fri), 2025,GCCL will be participating in BIO KOREA 2025,as a Business Partnering participant at COEX, Seoul.📍 BIO KOREA 2025 International Convention🗓️ May 7 (Wed) – 9 (Fri), 2025📌 COEX, Seoul / Exhibition & Business Partnering Participation🔗 Go to BIO KOREA Official Website✉️ Business Partnering Inquiry: GCCL@gccorp.comSince 2006, BIO KOREA has played a key role in enhancing the global presence of Korea’s healthcare industryand driving sustainable growth as a leading global convention in the biohealth sector.Celebrating its 20th edition this year, the BIO KOREA International Convention will featurea diverse range of programs including Business Partnering, Invest Fair, Exhibition, and Conferences. The biopharma industry is rapidly evolving with cutting-edge technologies like Digital Healthcare, AI-powered drug development, and novel modality platforms.Global collaboration is becoming increasingly important as these changes accelerate.At BIO KOREA 2025,GCCL will share our expertise and infrastructure as a global clinical bioanalytical partnerand engage in insightful discussions with pharmaceutical companies, CROs, and researchers from around the worldon current trends and innovations in the industry.GCCL offers:✅ Full-cycle clinical bioanalysis (Phase I to IV)✅ All-in-One analytical labs including Bioanalytical, Central, and R&D Labs✅ Compliance with GCLP and global regulatory standards (FDA/EMA)✅ Real-time sample tracking via LIMS and adoption of ddPCR and other advanced technologiesWe aim to be a trusted partner throughout your clinical development journey.Join us at BIO KOREA 2025 to explore the future of biohealth innovation and industry trends,and discover how partnering with GCCL can advance your global clinical development goals.As always, GCCL remains committed to being your most reliable clinical trial partner,ensuring the highest value and trust for our clients.We are committed to continuing as your trusted partner in clinical research. Click the banner below to learn more about GCCL!

Read more
GCCL Provides Full-Cycle Lab Services for the Approval of GC Biopharma’s Anthrax Vaccine

2025. 04. 17

GCCL Provides Full-Cycle Lab Services for the Approval of GC Biopharma’s Anthrax Vaccine

GCCL, as the central lab for the clinical development of GC Biopharma’s anthrax vaccine “BARYTHRAX(GC1109),” which was recently approved by the Ministry of Food and Drug Safety (MFDS), provided full-spectrum analytical support across the non-clinical and clinical phases, playing a pivotal role in the vaccine’s successful development.Jointly developed by GC Biopharma and the Korea Disease Control and Prevention Agency (KDCA) in preparation for national biosecurity threats such as bioterrorism, BARYTHRAX is Korea’s 39th domestically approved new drug, receiving MFDS approval on April 8, 2025.BARYTHRAX is the world’s first recombinant protein anthrax vaccine, created using genetic recombination technology to produce protective antigen (PA) proteins that deliver two types of anthrax toxin components into cells. This triggers an immune response via PA, effectively preventing anthrax infection. Throughout the vaccine’s development, GCCL provided end-to-end support—spanning bioanalytical method validation, sample analysis, central lab operations, and MFDS regulatory inspection readiness—ensuring analytical excellence at every step.✅ Validated Anti-PA IgG and TNA assays across the full clinical timelineIn the non-clinical stage, GCCL successfully conducted toxin neutralization assays (TNA) for protective antigens (PA) using rabbit serum samples.During clinical trials, ELISA-based Anti-PA IgG and TNA methods were rigorously validated following international guidelines.These validated methods were used for precise analysis of clinical samples, providing high-quality data throughout the study.✅ GCLP-certified central lab operations and multi-site coordinationAs a fully GCLP-certified central lab, GCCL oversaw the entire lifecycle of clinical sample management, including collection, transport, storage, preprocessing, and analysis across multiple clinical sites in Korea.Through systematic processes and stringent quality control, GCCL ensured data consistency and integrity,even in the complex landscape of multi-site clinical trials—contributing significantly to the reliability and success of the vaccine’s development.✅ Successful participation in MFDS regulatory inspectionGCCL also played a direct role in the MFDS clinical trial site inspection, successfully demonstrating the lab’s technical expertise and quality systems.Our data and management processes served as a critical foundation for regulatory approval,helping to bring Korea’s first anthrax vaccine to commercialization.We are proud to have meaningfully contributed to a project of national significance from beginning to end.This approval exemplifies how GCCL supports technological self-reliance in Korea’s vaccine development ecosystem.With world-class infrastructure and deep expertise in infectious disease analysis, GCCL remains committed to leading the delivery of high-quality analytical solutions for the development of vaccines and biopharmaceuticals worldwide.Click the banner below to learn more about GCCL!

Read more
GCCL’s Participation in the 2025 Spring Conference of KSCPT

2025. 04. 08

GCCL’s Participation in the 2025 Spring Conference of KSCPT

GCCL will participate as an exhibitor at the 2025 Spring Conference of the Korean Society for Clinical Pharmacology and Therapeutics (KSCPT), which will be held at Seoul National University Siheung Campus from Wednesday, April 16 to Thursday, April 17, 2025.  This year’s conference, held under the theme “Advancement of Clinical Pharmacology Research through Data Science,” will showcase a wide range of research achievements that apply cutting-edge data-driven technologies—such as real-world data (RWD), real-world evidence (RWE), machine learning, and artificial intelligence (AI)—to the field of clinical pharmacology.We are pleased to provide a brief introduction to the GCCL promotional booth that will be featured at this year’s conference. 🏢 GCCL Booth InformationDate & Time: Thursday, April 17, 2025 | 09:00–18:00Location: Booth No. 1, next to the registration desk, Seoul National University Siheung CampusOur affiliate company, C&R Research, will also be joining us at Booth No. 2. We look forward to seeing you there! :)Visitors to the GCCL booth will receive exclusive 2025 promotional items prepared by GCCL.By visiting our booth, you’ll have the opportunity to learn more about GCCL’s latest clinical trial sample analysis services. We warmly welcome your interest and visit!For more details, please refer to the promotional materials and link provided below.🔗 Conference Information: Learn MoreWe will continue to be your trusted partner in clinical trials, committed to delivering value and earning your confidence every step of the way. 

Read more